(redirected from Serine protease inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: deterrent
References in periodicals archive ?
A novel slow-tight binding serine protease inhibitor from eastern oyster (Crassostrea virginica) plasma inhibits perkinsin.
A dimeric 70-kDa chymotrypsin inhibitor with substantial N-terminal sequence homology to serine protease inhibitors was isolated from Acacia confusa seeds.
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.
2] Nonstandard abbreviations: SPINK1, serine protease inhibitor Kazal type 1; TATI, tumor-associated trypsin inhibitor; EGF, epidermal growth factor; ETS, E26 transformation-specific; EGFR, EGF receptor.
OTCBB: MCET), a leading supplier of immortalized non-tumorigenic human hepatocytes, announces the receipt of a new Small Business Innovation Research (SBIR) award to create proprietary BioFactories(TM) that express a serine protease inhibitor recently implicated as a novel treatment for sepsis.
In the new approach to serine protease inhibitor design, inhibitor binding is mediated by an intricate network of hydrogen bonds, some of which are very short, providing the stability required for the inhibitor to bind to the enzyme as a long-lived complex," according to Michael C.
Its lead indications are for the treatment of hereditary emphysema and asthma using the protein protease inhibitor alpha 1-antitrypsin (AAT), the prototypic member of the serine protease inhibitor superfamily known as serpins.
Additionally, the Company's serine protease inhibitor drug candidate, BCX-1470, designed to inhibit activation of the complement pathway, is in initial clinical trials.
In addition, the Company is in a clinical trial with its serine protease inhibitor drug candidate, BCX-1470, which is designed to inhibit activation of the complement pathway.
During the quarter, the Company completed a Phase I study of the safety, pharmacokinetics, and pharmacodynamics of an intravenous formulation of BCX-1470, a serine protease inhibitor, in normal healthy volunteers.
Food and Drug Administration (FDA) for an intravenous formulation of BCX-1470 in its serine protease inhibitor program.

Full browser ?